WILSON JOHN S 4

4 · BOND LABORATORIES, INC. · Filed Jan 3, 2013

Form 4

Period: 2012-12-28

DirectorCHIEF EXECUTIVE OFFICER

Transactions

Holdings

Stock Option
Exercise: $0.10From: 2011-06-08Exp: 2021-06-08→ Common Stock (500,000 underlying)
500,000
Warrant
Exercise: $0.15From: 2008-12-31Exp: 2013-12-31→ Common Stock (1,000,000 underlying)
1,000,000
Stock Option
Exercise: $0.09From: 2012-04-13Exp: 2017-04-13→ Common Stock (500,000 underlying)
500,000
Series C Convertible Preferred Stock
Exercise: $0.25→ Common Stock (668,000 underlying)
16.7
Warrant
Exercise: $0.30Exp: 2015-11-15→ Common Stock (332,500 underlying)
332,500

Footnotes (5)

[F1]The Reporting Person acquired the shares of the Issuer's common stock ("Common Stock") for aggregate consideration of $12,500 in a privately negotiated transaction.
[F2]The Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock ("Series C Preferred") contains a provision preventing the conversion of the Series C Preferred if, as a result of such conversion, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 4.99% of the Issuer's Common Stock issued and outstanding.
[F3]The Series C Preferred are perpetual.
[F4]Each share of Series C Preferred is convertible into that number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing $10,000 per share (the liquidation preference) by the conversion price then in effect, or $0.25 on the date of this Report. Conversion of the Series C Preferred is subject to the limitation on conversion described in Note 2.
[F5]The Warrant contains a provision preventing the exercise of the Warrant if, as a result of such exercise, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 9.99% of the Issuer's Common Stock issued and outstanding.

Documents

1 file